ClinicalTrials.gg
RecruitingNCT07218302Updated Jul 21, 2026

Eating Disorder Chatbot Optimization

A Phase 2 interventional study of Digital Chatbot Program in Eating Disorders, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 259 studies in Feeding and Eating Disorders with a site in United States — 35 open to participants now, 49 under way, none of them phase 3. Feeding and Eating Disorders · United States.

Planned enrollment
7th of 215
800 · median 66
Started
2026
with 13 others
Phase 2
14 of 259
3 open now
Primary completion
2029-07
later than 44 of 48 live
Registered
242nd of 259
by date

Among the 259 studies in Feeding and Eating Disorders with a site in United States, this one is the 7th largest by planned enrollment of the 215 interventional ones that give a count, is one of 14 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 44 of the 48 other live ones, and was the 242nd registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

35 of the 259 studies in Feeding and Eating Disorders with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 259 studies in Feeding and Eating Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to optimize an automated digital chatbot intervention for adults with clinical or subclinical eating disorders.

Read the detailed description

Eating disorders (EDs) are common-affecting an estimated 10% of individuals in their lifetimes-and have disabling consequences being associated with high psychiatric comorbidity, impairment, and mortality. Despite this, less than 20% of individuals with an ED ever receive treatment. When individuals do seek treatment, many are not evidence-based and come with high costs and burden on the healthcare system. One solution to this is a chatbot intervention that is evidence-based, affordable, and accessible for people with EDs. This project will assess four candidate components of a cognitive behavioral therapy (CBT)-based chatbot to determine the optimal chatbot package. CBT is the recommended first-line treatment for EDs, yet there is no research to date on which components are most effective or needed for meaningful change in ED psychopathology. In this study the intervention will be divided into four components targeting: (1) over-evaluation of weight and shape; (2) dietary restraint; (3) emotion dysregulation; and (4) resisting urges to binge. The investigators will recruit 800 adults with a binge/purge-type ED who are not currently in treatment and randomly assign participants to one of 16 experimental conditions (each combination from 1 to all 4 components) or the waitlist-control group. Participants will be assessed on changes in ED psychopathology, ED behavior frequencies, comorbid symptoms (i.e., depression, anxiety), and clinical impairment at 1-, 2-, and 6-months following randomization. An optimized package of these candidate components that is most effective, while remaining efficient, will be identified using multiphase optimization strategy (MOST). The investigators' established relationships with industry and non-profit partners will ensure this optimized package has high potential for scalability and dissemination into the community.

03

Conditions studied

  • Eating Disorders

Keywords

  • Eating Disorder Intervention
  • Eating Pathology
  • Eating Disorder Symptoms
  • Digital Mental Health
  • Chatbot
  • Optimization Randomized Control Trial
  • Multiphase Optimization Strategy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18+ years old
  • Owns a smartphone
  • Speaks English
  • US resident
  • Screens for a clinical or subclinical eating disorder
  • Low suicidality
  • Not currently in treatment for an eating disorder
  • Does not have a medical condition or take medications that impact appetite/weight
  • Not currently pregnant

Exclusion criteria

Exclusion Criteria:

  • Below 18 years of age
  • Does not own a smartphone
  • Does not speak English
  • Lives outside the US
  • Screens as: at risk for an eating disorder, anorexia nervosa, atypical anorexia nervosa, avoidant/restrictive food intake disorder, or not at risk for an ED
  • High suicidality
  • In treatment for an eating disorder
  • Has a medical condition or takes medication(s) that impact appetite/weight
  • Currently pregnant
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Chatbot targeting weight & shape over-evaluation (WSC)

    Participant will have access to the chatbot component addressing weight \& shape over-evaluation. Participant will receive scheduled targeted practice for the weight \& shape over-evaluation component. At any time, participant will have access to initiate practice in assigned study component.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting dietary restraint (DR)

    Participant will have access to the chatbot component addressing dietary restraint. Participant will receive scheduled targeted practice for the dietary restraint component. At any time, participant will have access to initiate practice in assigned study component.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting emotion dysregulation (ED)

    Participant will have access to the chatbot component addressing emotion dysregulation. Participant will receive scheduled targeted practice for the emotion dysregulation component. At any time, participant will have access to initiate practice in assigned study component.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting resisting urges to binge (UB)

    Participant will have access to the chatbot component addressing resisting urges to binge. Participant will receive scheduled targeted practice for the resisting urges to binge component. At any time, participant will have access to initiate practice in assigned study component.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting WSC and DR

    Participant will have access to the chatbot components addressing weight \& shape over-evaluation and dietary restraint. Participant will receive scheduled targeted practice for the weight \& shape over-evaluation and dietary restraint components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting WSC and ED

    Participant will have access to the chatbot components addressing weight \& shape over-evaluation and emotion deregulation. Participant will receive scheduled targeted practice for the weight \& shape over-evaluation and emotion dysregulation components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting WSC and UB

    Participant will have access to the chatbot components addressing weight \& shape over-evaluation and resisting urges to binge. Participant will receive scheduled targeted practice for the weight \& shape over-evaluation and resisting urges to binge components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting DR and ED

    Participant will have access to the chatbot components addressing dietary restraint and emotion deregulation. Participant will receive scheduled targeted practice for the dietary restraint and emotion dysregulation components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting DR and UB

    Participant will have access to the chatbot components addressing dietary restraint and resisting urges to binge. Participant will receive scheduled targeted practice for the dietary restraint and resisting urges to binge components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting ED and UB

    Participant will have access to the chatbot components addressing emotion dysregulation and resisting urges to binge. Participant will receive scheduled targeted practice for the emotion dysregulation and resisting urges to binge components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting ED; UB; and DR

    Participant will have access to the chatbot components addressing emotion dysregulation, resisting urges to binge, and dietary restraint. Participant will receive scheduled targeted practice for the emotion dysregulation, resisting urges to binge, and dietary restraint components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting ED; UB; and WSC

    Participant will have access to the chatbot components addressing emotion dysregulation, resisting urges to binge, and weight and shape over-evaluation. Participant will receive scheduled targeted practice for the emotion dysregulation, resisting urges to binge, and weight and shape over-evaluation components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting ED; DR; and WSC

    Participant will have access to the chatbot components addressing emotion dysregulation, dietary restraint, and weight and shape over-evaluation. Participant will receive scheduled targeted practice for the emotion dysregulation, dietary restraint, and weight and shape over-evaluation components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting UB; DR; and WSC

    Participant will have access to the chatbot components addressing resisting urges to binge, dietary restraint, and weight and shape over-evaluation. Participant will receive scheduled targeted practice for the resisting urges to binge, emotion dysregulation, dietary restraint and weight, and shape over-evaluation components. At any time, participant will have access to initiate practice in assigned study components

    Behavioral: Digital Chatbot Program

  • Experimental
    Chatbot targeting UB; DR; ED; and WSC

    Participant will have access to the chatbot components addressing resisting urges to binge, dietary restraint, emotion dysregulation, and weight and shape over-evaluation. Participant will receive scheduled targeted practice for the resisting urges to binge, emotion dysregulation, dietary restraint, emotion dysregulation, and weight and shape over-evaluation components. At any time, participant will have access to initiate practice in assigned study components.

    Behavioral: Digital Chatbot Program

  • No intervention
    Referral to seek services

    Those randomized to receive all chatbot components "off" will receive a referral to seek services.

Interventions

  • BehavioralDigital Chatbot Program

    Wysa is a digital rules-based chatbot program platform offering cognitive-behavioral therapy-based guided self-help modules. Participants in an arm with access to Wysa will engage with the digital chatbot program daily for eight weeks.

06

What researchers measure

Primary outcomes

  1. ED psychopathology; ED Examination-Questionnaire (EDE-Q)

    The EDE-Q is a 28-item inventory derived from an ED diagnostic interview, which asks self-reported concerns with weight and shape, and engagement in ED behaviors, over the last 28 days. Each item is scored from 0-6, with 0 being "No days" and 6 being "Every day". An average is taken of all items participants respond to for a total global score (with possible scores ranging from 0 to 6), where higher scores indicate greater symptomology.

    Time frame: 6 months

Secondary outcomes

  1. ED behaviors from the EDE-Q; Muscle Building Subscale from the Eating Pathology Symptoms Inventory (EPSI)

    The EDE-Q will also be used to gauge self-reported engagement in ED behaviors. Additionally, the EPSI Muscle Building subscale will be used which is a 5-item questionnaire that asks self-reported frequency of muscle building behaviors and attitudes over the last 28 days. Each item is scored from 0 ("Never") to 4 ("Very Often"). Subscale score is calculated by summing items participants respond to (scores may range from 0 to 20), and higher scores indicate greater symptomology.

    Time frame: 6 months

  2. Depression; Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a 9-item scale asking about self-reported depressive symptoms and suicidality over the past two weeks. All items are scored from 0 ("Not at all") to 3 ("Nearly every day"). Items participants respond to are summed (possible scores ranging from 0 to 27), and higher scores indicate greater symptomology.

    Time frame: 6 months

  3. Anxiety; Generalized Anxiety Disorder (GAD-7)

    The GAD-7 is a 7-item scale assessing self-reported symptoms of anxiety over the past two weeks. All items are scored from 0 ("Not at all") to 3 ("Nearly every day"). Items participants respond to are summed (possible scores ranging from 0 to 21), and higher scores indicate greater symptomology.

    Time frame: 6 months

  4. Clinical Impairment; Clinical Impairment Assessment (CIA)

    The CIA is a 16-item measure that assesses self-reported impairment, or impact on one's life, resulting from eating, weight, or shape in the last 28 days. All items are scores from 0 ("Not at all") to 3 ("A lot"). Items participants respond to are summed (possible scores ranging from 0 to 48), and higher scores indicate greater impairment.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Washington University in St. Louis
    St Louis, Missouri 63105, United States
    Recruiting
    • Marianna B. Horton, B.S./B.A. · Contactm.horton@wustl.edu · 3149355843
    • Ellen Fitzsimmons-Craft, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol and informed consent form

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2025
First posted
Oct 20, 2025
StartActual
Jul 17, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07218302
Responsible party
Ellen E. Fitzsimmons-Craft (Associate Professor of Psychological & Brain Sciences and Psychiatry, Washington University School of Medicine) — Principal investigator
First posted
Oct 20, 2025
Start date
Jul 17, 2026
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jul 21, 2026

Study contacts

Marianna B. Horton, B.S./B.A.
Contact
m.horton@wustl.edu
3149355843
Nathalie A. Gullo, B.S./B.A.
Contact
gullo@wustl.edu
6469195177
Ellen Fitzsimmons-Craft, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion